Versant Venture Management, LLC Buys CRISPR Therapeutics AG

San Francisco, CA, based Investment company Versant Venture Management, LLC buys CRISPR Therapeutics AG during the 3-months ended 2018-03-31, according to the most recent filings of the investment company, Versant Venture Management, LLC. As of 2018-03-31, Versant Venture Management, LLC owns 8 stocks with a total value of $313 million. These are the details of the buys and sells.

New Purchases: CRSP,

For the details of Versant Venture Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Versant+Venture+Management%2C+LLC

These are the top 5 holdings of Versant Venture Management, LLCCRISPR Therapeutics AG (CRSP) – 4,606,242 shares, 67.34% of the total portfolio. New PositionAudentes Therapeutics Inc (BOLD) – 1,204,615 shares, 11.58% of the total portfolio. Achaogen Inc (AKAO) – 1,281,152 shares, 5.31% of the total portfolio. Ocular Therapeutix Inc (OCUL) – 2,215,384 shares, 4.61% of the total portfolio. CymaBay Therapeutics Inc (CBAY) – 1,048,601 shares, 4.36% of the total portfolio. New Purchase: CRISPR Therapeutics AG (CRSP)

Versant Venture Management, LLC initiated holding in CRISPR Therapeutics AG. The purchase prices were between $23.48 and $58.17, with an estimated average price of $40.78. The stock is now traded at around $47.77. The impact to a portfolio due to this purchase was 67.34%. The holding were 4,606,242 shares as of 2018-03-31.

Here is the complete portfolio of Versant Venture Management, LLC. Also check out:

1. Versant Venture Management, LLC’s Undervalued Stocks
2. Versant Venture Management, LLC’s Top Growth Companies, and
3. Versant Venture Management, LLC’s High Yield stocks
4. Stocks that Versant Venture Management, LLC keeps buying

Leave a Reply

Your email address will not be published. Required fields are marked *